The Future of Human Longevity
Max Hodak, founder and CEO of Science Corporation, predicts that the first individuals to live to a thousand years old may already be alive today. This bold vision is based on current advancements in biotechnology and longevity research. The technology developed by Science, including a retinal implant to restore vision in blind patients, highlights the potential impact of BCIs on healthcare.
The Evolving Landscape of BCIs
Hodak emphasizes that BCIs are not a single product but a diverse category with multiple companies targeting different applications. The BCI technology developed by Science has treated over 40 patients, with 80% showing improved visual acuity. The technology uses a tiny array of solar panels to bypass damaged retinal cells, providing a visual signal back into the retina.
Ethical Considerations in BCI Deployment
Ethical considerations are crucial in the development and deployment of BCIs. Hodak stresses that the risk-reward balance should prioritize the most disabled patients who stand to gain the most from basic functionality. The brain’s plasticity, which allows it to adapt and learn from feedback, is a key factor in the potential success of BCIs.
Vision Restoration Technology
Hodak believes that in the next ten years, we could achieve close to native acuity in vision restoration technology. This advancement could transform the lives of visually impaired individuals and highlight the promise of BCIs in healthcare.